Person:
Domínguez Bernal, Gustavo Ramón

Loading...
Profile Picture
First Name
Gustavo Ramón
Last Name
Domínguez Bernal
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Veterinaria
Department
Sanidad Animal
Area
Sanidad Animal
Identifiers
UCM identifierORCIDScopus Author IDDialnet IDGoogle Scholar ID

Search Results

Now showing 1 - 4 of 4
  • Publication
    Veterinaria es calidad: Evaluación contínua y autoevaluación
    (2018-03-22) Olmeda García, Angeles Sonia; Lorenzo González, Pedro Luis; Fernández Álvarez, Manuela; Cambero Rodríguez, María Isabel; Domínguez Bernal, Gustavo Ramón; Sainz Rodríguez, Ángel; San Andrés Larrea, María Dolores de; Pérez Cabal, María de los Ángeles; Pérez Sen, Raquel; Barrero Rodríguez, Andrés
    El documento recoge los resultados del proyecto de Innova-Gestion UCM desarrollado durante los años 2016/2017 para la evaluación por rúbrica y online, formando, aplicando y analizando sus resultados. También se exponen los datos preliminares de la opinión de docentes y alumnos sobre su satisfacción con el actual Grado en Veterinaria. Estos resultados son, además, el punto de partida, para continuar mejorando la calidad de la docencia del centro.
  • Publication
    Immunization with the HisAK70 DNA Vaccine Induces Resistance against Leishmania Amazonensis Infection in BALB/c Mice
    (MDPI, 2019-11-14) Martínez Rodrigo, Abel; S. Dias, Daniel; Ribeiro, Patrícia A. F.; Roatt, Bruno M.; Mas Zubiri, Alicia; Carrión Herrero, Francisco Javier; Coelho, Eduardo A. F.; Domínguez Bernal, Gustavo Ramón
    Leishmania amazonensis is the aetiological agent of a broad spectrum of leishmaniosis in South America. It can cause not only numerous cases of cutaneous leishmaniosis but also diffuse cutaneous leishmaniosis. Considering the diversity of parasite species causing different forms of the disease that coexist in the same region, it is desirable to develop a vaccine capable of eliciting cross-protection. We have previously described the use of HisAK70 DNA vaccine for immunization of mice to assess the induction of a resistant phenotype against Leishmania major and infantum infections. In this study, we extended its application in the murine model of infection by using L. amazonensis promastigotes. Our data revealed that 14 weeks post-infection, HisAK70-vaccinated mice showed key biomarkers of protection, such as higher iNOS/arginase activity, IFN-γ/IL-10, IFN-γ/IL-4, and GM-CSF/IL-10 ratios, in addition to an IgG2a-type response when compared to the control group. These findings correlated with the presentation of lower footpad swelling and parasite burdens in the immunized compared to the control mice. Overall, this study suggests that immunization with HisAK70 may be considered a suitable tool to combat leishmaniosis as it is able to induce a potent cellular immune response, which allows to control the infection caused by L. amazonensis.
  • Publication
    Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection
    (Elsevier, 2019-08) Fernández-Cotrina; Javier; Belinchón-Lorenzo, Silvia; Arias, Pablo; Martínez Rodrigo, Abel; Mas Zubiri, Alicia; Orden Gutiérrez, José Antonio; Fuente López, Ricardo De La; Carrión Herrero, Francisco Javier; Domínguez Bernal, Gustavo Ramón
    HisAK70candidateshave successfullybeentested incutaneous (CL) andvisceral leishmaniosis (VL)mouse models.Here,weanalysedifferentbiomarkersindogtrialsafteraheterologousimmunizationstrategywitha HisAK70candidate(plasmidDNAplusadoptivetransferofperipheralblood-deriveddendriticcells(DCs)pulsed withthesamepathoantigenandCpGODNasanadjuvant)toexploretheantileishmanialactivityinanexvivo canineco-culturesysteminthepresenceofLeishmaniainfantumparasites.Inthecaninemodel,theheterologous HisAK70vaccinecoulddecreasetheinfectionindexintheDC-Tcellco-culturesystembyupto54%after30days andreachalmost67%after100dayspost-immunization,respectively,comparedtothoseobtainedinthecontrol groupofdogs.Theobservedsecurityandpotential tofight exvivoL. infantuminfectionhighlightaHisAK70 heterologousimmunizationstrategyasapromisingalternativetoevaluateitseffectivenessagainstcanineVL.
  • Publication
    Strength and medium-term impact of HisAK70 immunization in dogs: Vaccine safety and biomarkers of effectiveness for ex vivo Leishmania infantum infection
    (Elsevier, 2019-08) Martínez Rodrigo, Abel; Mas Zubiri, Alicia; Javier Fernández-Cotrina; Silvia Belinchón-Lorenzo; Orden Gutiérrez, José Antonio; Pablo Arias; Fuente López, Ricardo De La; Carrión Herrero, Francisco Javier; Domínguez Bernal, Gustavo Ramón
    HisAK70 candidates have successfully been tested in cutaneous (CL) and visceral leishmaniosis (VL) mouse models. Here, we analyse different biomarkers in dog trials after a heterologous immunization strategy with a HisAK70 candidate (plasmid DNA plus adoptive transfer of peripheral blood-derived dendritic cells (DCs) pulsed with the same pathoantigen and CpG ODN as an adjuvant) to explore the antileishmanial activity in an ex vivo canine co-culture system in the presence of Leishmania infantum parasites. In the canine model, the heterologous HisAK70 vaccine could decrease the infection index in the DC-T cell co-culture system by up to 54% after 30 days and reach almost 67% after 100 days post-immunization, respectively, compared to those obtained in the control group of dogs. The observed security and potential to fight ex vivo L. infantum infection highlight a HisAK70 heterologous immunization strategy as a promising alternative to evaluate its effectiveness against canine VL.